PTO/SB/96 (01-09)
Approved for use through 02/29/2009, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STÄTEMENT	INDER 37 CFR 3.73(b)
Applicant/Patent Owner: CIRC PHARMA RESEARCH AND DEVELOPMENT LIMITED	
Application No./Patent No.: 6,733,789	Filed/Issue Date: May 11, 2004
Titled: PRAVASTATIN PHARMACEUTICAL FORMUL	ATIONS AND METHODS OF THEIR USE
CIRC PHARMA RESEARCH AND DEVELOPMENT OF	orporation
(Name of Assignee)	(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.
states that it is:	
1. X the assignee of the entire right, title, and interest in;	
an assignee of less than the entire right, title, and in (The extent (by percentage) of its ownership interes	terest in t is %); or
3. the assignee of an undivided interest in the entirety	of (a complete assignment from one of the joint inventors was made)
the patent application/patent identified above, by virtue of eithe	
the United States Patent and Trademark Office at F copy therefore is attached.	plication/patent identified above. The assignment was recorded in teel, Frame, or for which a
B. A chain of title from the inventor(s), of the patent ap	plication/patent identified above, to the current assignee as follows:
1. From: Athpharma Lmited	To: Biovail Laboratories, Inc.
The document was recorded in the Unite	
Reel 014847 , Frame 0	040, or for which a copy thereof is attached:
2. From: Paul Stark, May Catherine Kelly, N	all M. Fang To: Elan Corporation, PLC
The document was recorded in the Unite	d States Patent and Trademark Office at
Reel 011531 Frame	or for which a copy thereof is attached.
3. From: Elan Corporation, PLC	To: Athpharma Limited
The document was recorded in the Unite	
Reel <u>013498</u> , Frame	
Additional documents in the chain of title are listed	
or concurrently is being, submitted for recordation pursu	
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]	
The undersigned whose tile is supplied below) is authorized to	o action behalf of the assignee.
	12th Warch 2009 Date
Signature	PRESIDE NT
SEAMUS MULLIGAN Printed or Typed Name	Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTD. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office; U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT BEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Continuation of Statement Under 37 CFR 3.73(b)

Patent No. 6,733,789 MULTIPARTICULATE BISOPROLOL FORMULATION

4. From: <u>Biovail Holdings Ltd./Biovail Laboratories Incorporated</u> To: <u>Biovail Laboratories (2005) Inc.</u>

Reel: <u>017971</u>, Frame: <u>0938</u>

5. From: Biovail Laboratories (2005) Inc.. To: Biovail Laboratories International SRL

Reel: <u>017982</u> Frame: <u>0102</u>

6. From: Biovail Laboratories International SRL To: Circ Pharma Research and

Development Limited

Reel: <u>019306</u> Frame: <u>0163</u>